Paediatric Breakthrough Pain Assessment
NCT06790719 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 210
Last updated 2025-01-24
Summary
Many children and young people with life-limiting and life-threatening illnesses get sudden bursts of pain called breakthrough pain. At the moment, there aren't any good ways to measure this pain in children and young people. The investigators are developing two questionnaires to help: one for patients to fill out themselves and another for parents or healthcare professionals to complete for younger children and young people who cannot explain their pain for themselves.
The investigators plan to work with 210 people across hospitals and hospices in England and Wales. This includes children and young people with life-limiting and life-threatening illnesses, their caregivers, and healthcare professionals. The investigators have already made a first version of the questionnaires.
The project has three main Studies:
In Study 1, the investigators will talk to 5-10 young patients and 5-10 caregivers about their experiences with breakthrough pain. The investigators will use their feedback to improve the questionnaires.
In Study 2, the investigators will ask 5-10 patients, 5-10 caregivers, and 5-10 healthcare professionals to fill out the questionnaires while speaking their thoughts out loud. This will help the investigators find any parts that are confusing or difficult to understand.
In Study 3, the investigators will test how well the questionnaires works. 80 patients, 40 caregivers, and 40 healthcare professionals will complete the questionnaires three different times to make sure they measure breakthrough pain as accurately as possible.
These questionnaire will be useful for hospitals and hospices across England and Wales to help them better manage pain, including breakthrough pain, in patients aged 3 months to 25 years who have life-limiting and life-threatening illnesses.
Conditions
- Breakthrough Pain
- Palliative Medicine
- Oncology Pain
- Pediatric ALL
- Young People
Sponsors & Collaborators
-
Great Ormond Street Hospital for Children NHS Foundation Trust
collaborator OTHER -
University of Southampton
lead OTHER
Principal Investigators
-
Christina Liossi, DPsych · University of Southampton
Eligibility
- Min Age
- 8 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-01-20
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
More Related Trials
-
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
NCT02932280 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Oxaliplatin in Treating Children With Advanced Solid Tumors
NCT00005844 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy
NCT04308642 ·Status: COMPLETED
-
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
NCT03936465 ·Status: COMPLETED ·Phase: PHASE1
-
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating Supportive Care for Children With Cancer: A Multi-Institutional Survey Study of Pediatric Oncology Patients and Parents
NCT01273194 ·Status: COMPLETED
-
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
NCT02847130 ·Status: COMPLETED
-
Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours
NCT02303028 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer
NCT00897871 ·Status: UNKNOWN
-
Evaluation of Proton Therapy in Pediatric Cancer Patients
NCT03223766 ·Status: ACTIVE_NOT_RECRUITING
-
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
NCT00083070 ·Status: COMPLETED ·Phase: PHASE1
-
Antibiotic Resistance in Global Pediatric Oncology Centers
NCT03721562 ·Status: COMPLETED
-
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
NCT00025064 ·Status: UNKNOWN ·Phase: PHASE2
-
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy and/or Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
NCT00417014 ·Status: UNKNOWN ·Phase: NA
-
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
NCT00352027 ·Status: COMPLETED ·Phase: PHASE2
-
The Decision To Enroll In Therapeutic Clinical Trials In A Pediatric Cancer Clinical Network
NCT05454618 ·Status: RECRUITING
-
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT07043894 ·Status: RECRUITING ·Phase: PHASE2
-
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
NCT00003735 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
NCT00101270 ·Status: COMPLETED ·Phase: PHASE1
-
Pediatric Radiation Therapy Registry
NCT07129317 ·Status: RECRUITING
-
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
NCT00001686 ·Status: COMPLETED
-
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
NCT00057811 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
NCT01962103 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259 ·Status: COMPLETED ·Phase: PHASE3